Is Crossject S.A. (ALCJ.PA) a Buy, Sell, or Hold?
PAR : ALCJ.PA
Crossject S.A.
$1.5 EUR
$0 (0.0%)
- Volume
- 341.99K
- Average Volume
- 311.16K
- Market Capitalization
- $89.91M
- P/E Ratio
- -7.25
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.70
- Year Low
- $1.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.35
Company Overview
PAR
Patrick Alexandre
Medical - Instruments & Supplies
Healthcare
ALCJ.PA
99
FR
EUR
Liquidity Metrics
-4.07
2.35
1.82
0.77
0.00
Sales & Valuation
-$
60.63
-16.09
-8.29
-0.21
Profitability
-$0.2
-$10.37M
-699.06%
-889.01%
299.54%
-34.07%
P/E Metrics
-7.25
-0.26
-0.26
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-0.45
4/9
$8.87M
$30.43M
$35.3M
-$15.09M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Patrick Alexandre | Co-Founder, Chief Executive Officer & Chairman of the Executive Board |
| Dan Chiche | Chief Medical Officer North America |
| Isabelle Liebschütz | Chief Quality & Regulatory Officer and Member of Executive Board |
| Lionel Seltz | Chief Financial Officer |
| Tony Tipton | Chief Operating Officer of U.S |
Poll Results
No votes yet today — be the first to share your view!
About Crossject S.A. (PAR:ALCJ.PA) Stock
Crossject S.A. is dedicated to pioneering needle-free drug delivery solutions. A key innovation from the company is ZENEO, a prefilled, single-use auto-injector that eliminates the need for a traditional needle. Crossject is actively advancing a portfolio of drugs through clinical trials, all intended for administration via its ZENEO system. This pipeline includes Sumatriptan for treating migraines and cluster headaches, Adrenaline for severe allergic reactions (anaphylactic shock), Hydrocortisone for acute adrenal insufficiency, Midazolam for managing epileptic seizures, Naloxone for opioid overdose, Apomorphine for temporary paralysis in Parkinson's patients, Methotrexate for rheumatoid arthritis, and Terbutaline for acute asthma attacks. Founded in 1997, the company maintains its operat ... ional base in Dijon, France.
Frequently Asked Questions
-
What is the current Crossject S.A. (ALCJ.PA) stock price?
-
Crossject S.A.(PAR:ALCJ.PA) stock price is $1.5 in the last trading session. During the trading session, ALCJ.PA stock reached the peak price of $2.695 while $1.346 was the lowest point it dropped to. The percentage change in ALCJ.PA stock occurred in the recent session was 0.0% while the dollar amount for the price change in ALCJ.PA stock was $0.
-
ALCJ.PA's industry and sector of operation?
-
The PAR listed ALCJ.PA is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of ALCJ.PA?
-
Patrick Alexandre | Co-Founder, Chief Executive Officer & Chairman of the Executive Board
Dan Chiche | Chief Medical Officer North America
Isabelle Liebschütz | Chief Quality & Regulatory Officer and Member of Executive Board
Lionel Seltz | Chief Financial Officer
Tony Tipton | Chief Operating Officer of U.S -
How many employees does ALCJ.PA have?
-
Number of ALCJ.PA employees currently stands at 99. ALCJ.PA operates from 6 Rue Pauline Kergomard, Dijon, BF 21000, FR.
-
Link for ALCJ.PA official website?
-
Official Website of ALCJ.PA is: https://www.crossject.com
-
How do I contact ALCJ.PA?
-
ALCJ.PA could be contacted at phone #33 3 80 54 98 50 and can also be accessed through its website. ALCJ.PA operates from 6 Rue Pauline Kergomard, Dijon, BF 21000, FR.
-
How many shares of ALCJ.PA are traded daily?
-
The average number of ALCJ.PA shares traded daily for last 3 months was 311.16K.
-
What is the market cap of ALCJ.PA currently?
-
The market value of ALCJ.PA currently stands at $89.91M with its latest stock price at $1.5